Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

Journal of the National Cancer Institute

Volumn 98, Issue 21, 2006, Pages 1521-1527

  Carter, H Ballentine ^a   Ferrucci, Luigi ^b   Kettermann, Anna ^a   Landis, Patricia ^a   Wright, E James ^a   Epstein, Jonathan I ^a   Trock, Bruce J ^a   Metter, E Jeffrey ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGING; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 33750582502     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj410     Document Type: Article

References (22)

1. United States Department of Health and Human Services (Agency for Healthcare Research and Quality). U.S. Preventive Services Task Force, 2002. Available at: http://www.ahcpr.gov/clinic/uspstf/ uspsprca.htm#summary. [Last accessed: May 31, 2005.]
2. Zhu H, Roehl KA, Antenor JA, Catalona WJ. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: A preliminary analysis. Urology 2005;66:547-51.
3. Carter HB. Prostate cancers in men with low PSA levels - must we find them? N Engl J Med 2004;350:2292-4.
4. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: Implications of various definitions for abnormal. J Natl Cancer Inst 2005;97:1132-7.
5. Carter HB, Pearson JD, Metter JE, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215.
6. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163-7.
7. Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy. J Urol 1997;158:1876-8.
8. Egawa S, Arai Y, Tobisu K, Kuwao S, Kamoto T, Kakehi Y, et al. Use of pretreatment prostate specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000;3:269-74.
9. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
10. Shock NW, Greulich RC, Andres R, Arenberg D, Costa PT Jr, Lakatta EG, et al. Normal human aging: The Baltimore Longitudinal Study of Aging. Washington (DC): US GPO (NIH publication no. 84-2450); 1984.
11. Rock RC, Chan DW, Bruzek D, Waldron C, Oesterling J, Walsh P. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. Clin Chem 1987;33:2257-61.
12. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database. Available at: http://www.seer.cancer.gov. [Last accessed: May 31, 2005.]
13. Lindstrom MJ, Bates DM. Newton-Raphson and EM algorithms for linear mixed-effects models for repeated-measures data. J Am Stat Assoc 1988;83:1014-22.
14. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868.
15. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-65.
16. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 2006;67:343-8.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer: A new concept. Urol Clin North Am 1993;20:665-70.
19. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
20. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53:581-9.
21. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM. Long-term effects of finasteride on prostate specific antigen levels: Results from the prostate cancer prevention trial. J Urol 2005:174: 877-81.
22. Ross K, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate specific antigen screening strategies for prostate cancer detection. JAMA 2000;284:1399-405.